Synbiotics and Growth

Nestlé

Status and phase: Completed; Phase 3

Conditions: Infants Growth

Treatments: Other: Infant formula; Other: Breastfeeding

Study type: Interventional

Funder types: Industry

Identifiers

NCT01886898

05.23.INF

Details and patient eligibility

About

The primary objective of the trial is to assess the growth of the infants enrolled into the study. Other parameters to be measured include microbiota balance and certain blood biochemical values. In addition the infants' digestive tolerance of the formulae and frequency of morbidity will be investigated.

Full description

The infants will be recruited between birth and 14 days of life and will start on the allocated study formula as soon as they are enrolled. In practice this will tend to be immediately after birth. The treatment period, in terms of data necessary for the primary outcome, will be until they reach 16 weeks old. Growth and other measurements will be collected on five separate occasions during this period, ie 2, 4, 8, 12 and 16 weeks of life. Although the study intervention formally ends at 16 weeks, it will be useful to have a follow up visit at 26 weeks to collect further data on the gut microflora in the sub-group of infants who have already provided a stool sample at 8 weeks. This follow-up visit will be of benefit to the subject as they receive a weight check and clinical examination by a paediatrician and will be offered to all subjects (no invasive procedures will be carried out).

Enrollment: 311 patients

Sex: All

Ages: Under 14 days old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy new-born infant
• Infant is less14 days old on day of enrollment
• Birthweight between 2500g and 4500g
• Gestational age over 37 weeks
• Singleton birth
• Infant's mother, before the 14th day of the child's life, has elected not to breastfeed
• Infant randomized in to a treatment group can expected to be exclusively fed the formula from enrolment until 16 weeks old
• Having obtained his/her legal representative's informed consent

Exclusion criteria

• Currently participating in another clinical trial
• Congenital illness or malformation that may affect normal growth
• Significant pre-natal and/or post-natal disease
• Re-hospitalisation for more than 2 days in the first 14 days of life. (Exceptionally, infants re-hospitalized because of jaundice may be enrolled in the study).
• Receiving antibiotic treatment at time of enrolment or in the 5 previous days.
• Receiving infant formula containing probiotics and/or prebiotics at the time of enrolment

Trial design

311 participants in 4 patient groups, including a placebo group

Standard starter infant formula

Placebo Comparator group

Description:

starter infant formula from enrollment till 16 weeks of age

Treatment:

Other: Infant formula

starter infant formula with prebiotics

Experimental group

Description:

starter infant formula from enrollment till 16 weeks of age

Treatment:

Other: Infant formula

starter infant formula with pro and prebiotics

Experimental group

Description:

starter infant formula from enrollment till 16 weeks of age

Treatment:

Other: Infant formula

breastfeeding group

Other group

Description:

exclusively breastfeeding during the first 16 weeks of age

Treatment:

Other: Breastfeeding